We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00968851
Recruitment Status : Completed
First Posted : August 31, 2009
Last Update Posted : April 25, 2014
Syneos Health
Information provided by (Responsible Party):
FORUM Pharmaceuticals Inc

Brief Summary:
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.

Condition or disease Intervention/treatment Phase
Schizophrenia Central Nervous System Diseases Cognition Drug: EVP-6124 Drug: Placebo Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled, Phase 2 safety/efficacy study in which two dose levels of EVP-6124 will be evaluated. Eligible for enrollment will be patients who meet clinical criteria for schizophrenia and who are taking chronic atypical anti-psychotic medication at a stable dose. This study will therefore evaluate the effects of EVP-6124 when administered concomitantly with anti-psychotic medication.

Patients will be randomized to one of the following groups: 0.3 mg or 1.0 mg EVP-6124, or placebo. Seventy-five patients per group. Study drug will be supplied as capsules and will be orally administered once daily for a total of 84 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 317 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Study Start Date : December 2009
Actual Primary Completion Date : January 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Active Comparator: EVP-6124 0.3 mg
one 0.3 mg capsule every day for 84 days
Drug: EVP-6124
Arms: 1

Active Comparator: EVP-6124 1.0 mg
one 1.0 mg capsule every day for 84 days.
Drug: EVP-6124
Arms: 2

Placebo Comparator: Placebo
Placebo every day for 84 days
Drug: Placebo
Arm: 3

Primary Outcome Measures :
  1. Safety and efficacy of two doses of EVP-6124 (0.3, and 1.0 mg QD) versus placebo capsules (QD) for 84 days to subjects with schizophrenia who are on chronic stable atypical anti-psychotic therapy as determined by clinical safety and cognitive function. [ Time Frame: 84 days ]

Secondary Outcome Measures :
  1. Assessment of Clinical Efficacy [ Time Frame: 84 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who meet clinical criteria for schizophrenia or schizo-affective disorder utilizing the structured clinical interview (SCI)
  • Must be treated with a second generation anti-psychotic drug other than clozapine at a stable dose for at least 4 weeks and must have been on that drug and clinically stable for at least 8 weeks
  • Must have no more than "moderate" severity rating for negative symptoms: BPRS item ≤4
  • A minimal level of extrapyramidal symptoms (EPS); Simpson-Angus Scale total score ≤6
  • A minimal level of depression; Calgary Depression Scale total score ≤10
  • Must have a general health status acceptable for participation in a 12-week clinical trial
  • Fluency (oral and written) in the language in which the standardized tests will be administered
  • If a smoker, the ability to refrain from smoking for at least 30 minutes prior to any cognitive testing

Exclusion Criteria:


  • Insufficiently controlled diabetes mellitus in the judgment of the investigator
  • Malignant tumor within the last 5 years with the exception of squamous and basal cell carcinoma or cervical carcinoma it situ
  • Pregnancy, nursing, (or if fertile female) not willing to utilize birth control measures during study
  • Unstable medical condition that is clinically significant in the judgment of the investigator: major organ system dysfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968851

Show Show 31 study locations
Sponsors and Collaborators
FORUM Pharmaceuticals Inc
Syneos Health
Layout table for investigator information
Study Director: Chris Southard Syneos Health
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT00968851    
Other Study ID Numbers: EVP-6124-009
First Posted: August 31, 2009    Key Record Dates
Last Update Posted: April 25, 2014
Last Verified: March 2012
Keywords provided by FORUM Pharmaceuticals Inc:
Central nervous System Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Diseases
Central Nervous System Diseases
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders